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1. Introduction
Down Syndrome (DS) is caused by trisomy of Hsa21 in humans [1]. It is the most common
autosomal aneuploidy, occurring in about 1 in 700 live births [2]. The clinical features of DS
are variable and affect many different aspects of development. In any given individual, there
may be over 80 different clinical traits [3]. Major clinical features associated with DS include
the distinctive craniofacial appearance, reduced size and altered morphology of the brain,
cognitive impairments, hearing loss and defects of the gastrointestinal, immune and endocrine
systems [3]. Whilst this constellation of anomalies has been described we are still far from
understanding their cause. How does an extra set of normal Hsa21 genes result in whole body
system disturbances and what are the molecular genetics bases for these disturbances?
A large number of genes are simultaneously expressed at abnormal levels in DS, therefore, it is
a challenge to determine which genes contribute to specific abnormalities, and then identify the
key molecular pathways involved. We are advocates of the approach articulated by Nadel [4] -
that a careful and detailed analysis of the clinical defects in humans be followed by the crea‐
tion of mouse models that over-express only some of the genes triplicated on Hsa21, so that the
genes responsible for specific features of the DS phenotype can be identified. We generated mice
in which the RCAN1 gene is over-expressed (RCAN1-TG) to study the consequences of excess
RCAN1 and thus investigate its potential contribution to the DS phenotype. Our research adds
to the growing body of work assigning specific functions to particular Hsa21 genes. Other
examples under study with a particular focus on brain function include, DYRK1A [5], SOD1 [6],
APP [7] [8] [9], SNYJ1 [10] and ITSN1 [11]. Once we understand the abnormalities caused by
subtle over-expression of single genes, we can embark on a programme to generate mice
expressing combinations of genes to examine potential additive effects. This sort of approach is
consistent with the idea that the DS phenotype results from disturbances in biological path‐
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ways due to an accumulation of subtle changes brought about by the effects of the over-
expression of many single genes. Indeed, such an approach is bearing fruit already - RCAN1 and
DYRK1A have been shown to act cooperatively to destabilise a calcineurin regulatory circuit
when the genes are over-expressed in a combinatorial fashion [12].
The focus of this chapter will be to provide insight into RCAN1 and its functions, and examine
the evidence to suggest that this gene plays a role in the neurological, immune and vascular
systems. We will firstly give an overview of the gene family to which RCAN1 belongs; followed
by a description of the functional domains of the protein product, including post translational
modification domains; its tissue expression pattern; cellular pathways involving RCAN1; and
finally, how its over-expression may contribute to the neurological, immune and cancer
phenotypes associated with DS.
2. The RCAN gene family
DSCR1, renamed RCAN1, was first described by our group in 1995 after a search for genes located
on Hsa21 with the potential to be involved in DS [13]. RCAN1 is a member of a family of calcineurin
binding proteins and is conserved across species, from lower unicellular eukaryotes such as
yeast to complex organisms including humans [14]. The high level of interspecies homology of
this protein has been taken to indicate a conserved role during evolution [15] [16]. A number of
different genes belonging to this family have now been identified in humans, including, RCAN1,
RCAN1L2, RCAN2 and RCAN3 [15, 17]. The family was identified based on the presence of a
short “signature” polypeptide FLISPPxSPP (part of the so called SP motif) [18] but there is a high
degree of similarity across the entire protein in all RCAN family members. All members perform
similar functions. For example, RCAN2 interacts with calcineurin with similar efficiency to
RCAN1 [19] and the human gene can functionally replace the yeast gene [18]. Interestingly, while
RCAN family members are all expressed in similar tissues, each family member displays a distinct
expression profile. For instance, while all family members were expressed in the brain, each
displayed different levels of expression, depending on the region and developmental stage
examined [20]. Within these regions there were also differences in the cellular and subcellular
location of the family members. RCAN1 was highly expressed in neurones and in the neutro‐
pil, while RCAN1L2 was expressed in scattered neurones and was the only RCAN family member
detected in glial cells [20, 21]. The differential expression pattern of the RCAN family mem‐
bers in the brain indicates that they are all likely to be important in brain development and
function, yet each member may be functionally distinct [20].
3. General tissue and cellular expression of RCAN1
The RCAN1 gene spans about 100 kb of genomic DNA and consists of seven exons and six
introns. Of the seven exons, the first four are alternative first exons (RCAN1-1 to RCAN1-4
containing exons 1 to 4, respectively). RCAN1 encodes two major protein isoforms, RCAN1-1
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and RCAN1-4. RCAN1-1 protein consists of 252 amino acids, while RCAN1-4 is a shorter, 197
amino acid protein [22, 23]. Using Northern blot analysis, RCAN1-1 and RCAN1-4 were found
to be similarly distributed throughout the body [22]. RCAN1-1 was highly expressed in the
foetal brain and in the adult brain, heart and skeletal muscle. Lower levels were detected in
the foetal lung, liver and kidney and in the adult pancreas, lung, liver and placenta. High levels
of RCAN1-4 were detected in the foetal kidney and in adult heart, skeletal muscle and placental
tissues, with lower levels in the foetal brain, lung and liver and adult lung, liver, kidney and
pancreas. While both isoforms exhibited a similar expression pattern, only very low levels of
RCAN1-4 were found in the adult brain and RCAN1-1 expression could not be detected in the
adult kidney [13, 22]. Northern blot and RT-PCR failed to detect exon 3 in any of the foetal or
adult tissue studied, while isoform 2 was found only in the foetal brain and liver [22].
RCAN1-1 and RCAN1-4, the most predominantly expressed isoforms, are under the control
of different promoters and are therefore likely to have different regulatory mechanisms and
possibly even different functions. For example, RCAN1-4 expression is regulated by calcium
signalling. Experiments in PC-12 cells (a neuronal like cell line) found that when intracellular
calcium levels increased through membrane depolarisation, RCAN1-4 gene expression was
rapidly induced [24] and this was mediated by the calcineurin/Nuclear factor activated T cells
(NFAT) signalling pathway [24]. Studies on the RCAN1-4 promoter identified the presence of
putative NFAT binding sites. No study published to date has demonstrated Ca2+/calcineurin-
mediated expression of RCAN1-1. Interestingly, RCAN1 is able to function in an autoinhibitory
manner as over-expression of any RCAN1 isoform resulted in an inhibition of RCAN1-4 gene
expression [24].
The subcellular location of RCAN1 protein was initially determined using tranfection of a
RCAN1-GFP protein construct in C2C12 cells, a mouse myoblast cell line. RCAN1 protein was
located in both the nuclear and cytosolic compartments and in the absence of treatments to
activate the calcineurin signalling pathway, resided predominantly in the nucleus [25]. Various
physiological and biochemical stresses have been demonstrated to influence the location of
RCAN1 within a cell. For example, under normal circumstances RCAN1 was located within
the nuclear compartment in various cell lines, including HT-1080 fibrosarcoma and I251
astroglioma cells. However, when these cells were subjected to oxidative stress, RCAN1
protein was redistributed to the cytoplasm [26]. The same observation was made following
activation of the calcineurin signalling pathway, which resulted in the translocation of RCAN1
from the nucleus into the cytosolic compartment [27].
4. Functional domains of the RCAN1 protein
Initial studies found that both RCAN1 isoforms encode a proline rich protein consisting of a
putative acidic domain, a serine proline motif, a putative DNA binding domain and a proline
rich region typical of a SH3 domain ligand [22, 28]. These structural motifs are typically seen
in proteins involved in transcriptional regulation and signal transduction. A more recent study
on RCAN1 proteins in dozens of species revealed 4 highly conserved regions separated by
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other regions that are less well conserved. These four regions consist of: a region at the amino
terminus capable of forming an RNA recognition motif; the gene family signature domain
consisting of the highly conserved SP motif; a PxIxIT-like domain (x represents any amino
acid) and a C-terminal TxxP motif [29] (see Figure 1). The functions of these highly conserved
regions in RCAN1 proteins are yet to be fully explored.
Figure 1. Schematic representation of the major RCAN1 protein isoforms. Protein motifs are shown: the RRM
(RNA recognition motif); the SP (serine / proline) motif incorporating the LxxP, family signature and ExxP domains; the
PxIxIT-like domain; and the TxxP motif. Serines 108 and 112 in RCAN1-4 are also indicated.
The most highly conserved region in the RCAN1 protein is the SP motif. This motif is similar
to that present in NFAT proteins [30]. In vitro, the SP motif is able to bind to and inhibit
calcineurin activity, however studies in cell lines have suggested that it is not necessary or
sufficient to achieve this. By generating various deletion-constructs of the RCAN1 coding
sequence it was found that RCAN1 was able to inhibit calcineurin in C2C12 myoblasts even
when the SP domain was absent [31]. This study determined that two additional domains, one
at the N-terminus, the other in the distal C-terminal region, were required to inhibit calcineurin
activity [31]. Use of a truncated version of the RCAN1 protein also demonstrated that the last
33 amino acids were essential for nuclear localisation. In the absence of this 33 amino acid
domain (which contains the SP motif and a region identified as a SH2 domain) RCAN1 protein
accumulated in the cytoplasm [25].
Site-directed mutagenesis studies have shown that phosphorylation of the RCAN1 protein
regulates its function, subcellular location and stability. Indeed, RCAN1 can be phosphory‐
lated by various kinases at a number of different sites to change its activity towards calcineurin.
For example, the serine residue within the SP domain at position 112 (Ser112) (Ser167 in
RCAN1-1) is variously phosphorylated by BMK1 [32], NIK [33] and DYRK1 [34] and acts as a
priming site for subsequent phosphorylation at Ser108 (Ser163 in RCAN1-1) by GSK-3 [35] [31]
[34]. Phosphorylation by TAK1 at Ser94 and Ser136 [36] and by DYRK1A at Thr193 [34] also change
the activity of RCAN1 towards calcineurin (see later). NIK-mediated phosphorylation [33] or
phosphorylation by PKA [37] augmented the half-life of RCAN1 protein. And, phosphoryla‐
tion of a threonine residue (Thr166 in RCAN1-4) in the SH2 domain controlled its subcellular
localisation since exchanging the threonine for an alanine resulted in an accumulation of
RCAN1 protein within the cytoplasm [25]. Thus, nuclear localisation of RCAN1 is controlled,
at least in part, by phosphorylation.
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Other studies have shown that RCAN1 is cleaved by calpain and this cleavage appears to
increase the stability of the protein by decreasing its proteasome-dependent degradation [38].
Further, the cleavage of RCAN1 by calpain also affects its interactions with other proteins. For
example, cleavage of RCAN1-4 by calpain abolished its ability to bind to Raf-1 [38]. Yet another
pathway involved in the post translational regulation of RCAN1 is the ubiquitin-proteasome
system (UPS). The UPS is important in the regulation of protein turnover in response to
changing cellular conditions and facilitates the degradation of defective proteins [39]. Ubiq‐
uitin is a polypeptide able to bind to lysine residues on proteins targeted for degradation. This
binding occurs through sequential steps mediated by ubiquitin-activating enzyme (E1),
ubiquitin-conjugating enzyme (E2) and ubiquitin-protein ligase (E3) [40]. Following this
sequence of events, the 26s proteasome is able to recognise and degrade the poly-ubiquinated
protein. The first evidence to suggest that RCAN1 was degraded by the ubiquitin pathway
came from yeast two hybrid and co-immunoprecipitation experiments which found that
RCAN1-4 interacted with ubiquitin [41]. More recent studies demonstrated that RCAN1
interacts with other members of the UPS, including, Skp1, Cullin/Cdc53, F-box protein Cdc4
(SCFCdc4) [42] and SCFβ TrCP1/2 [40]. The interaction between RCAN1 and the UPS is not only
important in regulating turnover of the RCAN1 protein but may also influence its function.
For example, increased degradation of RCAN1 by SCFCdc4 diminished its ability to inhibit
calcineurin signalling [42].
5. RCAN1 function—Signal transduction pathways
Interest in RCAN1 surged after the discovery that it encoded a protein capable of inhibiting
the protein serine/threonine phosphatase calcineurin (PP2B/PPP3C) [19] [27] [31] [43] [44].
RCAN1 has since been implicated in a variety of cellular processes, including oxidative stress
[45] [46] [47] [48], angiogenesis [49], mitochondrial function [50] and immune responses and
inflammation [44] [51]. Participation of RCAN1 in these processes has been mostly attributed
to its interaction with the calcineurin pathway. Nonetheless, calcineurin-independent activi‐
ties have been demonstrated [51] [52] [53] [54] [55]. Recently, RCAN1 mRNA and protein was
found to increase in the peri-infarct region following middle cerebral artery occlusion (MCAO)
in mice [56] and its up regulation was found to be protective [57].
5.1. The calcineurin pathway
The calcineurin pathway plays an integral role in the development and homeostatic regulation
of a number of different cell types, including immune cells and neurones. The pathway is
activated by increases in intracellular calcium (Ca2+) due to oxidative stresses, chemical-
mediated calcium increases and in response to biomechanical strain [58]. An increase in
intracellular Ca2+ leads to the activation of calmodulin, which forms a complex with calcineurin
to activate its phosphatase function. Activated calcineurin then dephosphorylates cytosolic
NFAT leading to its translocation to the nucleus where it complexes with GATA-4 [59] allowing
DNA binding and facilitation of the transcription of numerous gene targets [60].
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RCAN1 interacts directly with calcineurin [19] [27]. Calcineurin is a heterodimer, consist‐
ing of a catalytic A subunit and a calcium binding regulatory B subunit [61]. RCAN1 is able
to bind to the A subunit in a linker region between the calcineurin A catalytic domain and
the calcineurin B binding region [19]. Deletion of the carboxyl-terminal half of the catalytic
domain of calcineurin A abolished binding with RCAN1, indicating that this region was
critical for the interaction [27]. Studies with RCAN1 have shown that exon 7 is able to bind
to and regulate the activity of calcineurin and this binding occurs with a very high affinity
[62]. While binding of RCAN1 to calcineurin did not interfere with the interaction between
calcineurin and calmodulin, it is believed to interfere with the ability of calcineurin to bind
NFAT by competing with the NFAT binding site  [31].  Indeed,  when RCAN1  was over-
expressed, it inhibited the activity of an exogenously added constitutively active calcineur‐
in and transcription of a number of calcineurin-dependent genes including IL-2 and MEF2
was prevented [27]. RCAN1 over-expression was found to inhibit NFAT translocation to the
nucleus,  thus inhibiting calcineurin-dependent gene transcription [19] but was unable to
inhibit a constitutively active form of NFAT demonstrating that the inhibition of calcineur‐
in signalling was through calcineurin, rather than interference with downstream compo‐
nents of the pathway [27].
Interestingly, activation of calcineurin signalling induces RCAN1-4 expression [18, 19]. This
occurs through a 900 base pair sequence located between exons 3 and 4 in an intragenic
promoter region for RCAN1-4, which contains a dense cluster of consensus binding sites for
the NFAT transcription factor [61]. The existence of such a site suggested that RCAN1
participates in a negative feedback loop, presumed to exist to prevent the adverse effects of
unrestrained calcineurin activity following prolonged Ca2+ stimulation [27]. Indeed, following
induction of the calcineurin pathway, levels of RCAN1-4 mRNA increased within 1.5 hours
and peaked 6 hours after treatment with a calcium stressor [45].
As more and more studies have emerged on RCAN1 and the propagation of calcium signals
in the cell, it has become clear that the role of RCAN1 is not always to inhibit the calcineurin
pathway. While the earliest studies found RCAN1 to negatively regulate the pathway, in other
circumstances it seems to facilitate calcineurin activity. Indeed, contrary to expectations it was
found that the absence of Rcan1 diminished calcineurin signalling in yeast [18]. Similar results
were found when Rcan1 expression was disrupted in mice. Rcan1-null mice exhibited an
unexpected decrease in calcineurin activity in the heart under normal physiological conditions
and after stress [63] and a reduction of calcineurin activity was concomitant with reduced
nuclear distribution of NFAT and a loss of NFAT-dependent gene transcription [64].
These apparently paradoxical actions of RCAN1 may be explained, at least in part, by its
cellular concentration, its nuclear or cytosolic localisation and/or its phosphorylation status
[64] [35] [32] [65] [25]. For example, the abundance of RCAN1 in the cell may determine its
ability to either enhance or inhibit calcineurin signalling. Low or intermediate levels of RCAN1
were shown to facilitate calcineurin signalling while very high levels of over-expression were
inhibitory, suggesting that RCAN1 oscillates between stimulatory and inhibitory forms
depending on its concentration [35] [138]. In contrast, in another study, the functional role of
RCAN1 was found to change in a dose-dependent fashion, but in the opposite direction to the
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aforementioned studies – RCAN1 was an inhibitor at low levels but a facilitator when levels
were high [66]. Another study indicated that 4 highly conserved domains in the RCAN1
protein were important in determining its activity towards calcineurin. Specifically, that
preferential binding of RCAN1 to calcineurin prevented NFAT binding resulting in inhibition
of calcineurin signal transduction due to competition between RCAN1 and NFAT for calci‐
neurin docking sites [29]. This preferential binding occurred in the presence of high levels of
Rcan1 and required the LxxP domain within the SP motif and the PxIxIT domain [29].
Conversely, when Rcan1 was expressed at lower levels, the protein was able to stimulate
calcineurin signalling. This stimulatory effect required the LxxP and ExxP domains within the
SP motif as mutations within both of these domains prevented stimulation.
Other studies have suggested that it is the phosphorylation status of RCAN1 that determines
its action as either an inhibitor or facilitator of calcineurin activity. A study in yeast found that
for Rcan1 to facilitate calcineurin signalling it required phosphorylation of both serine residues
located within the SP motif by a priming kinase (in this case MAPK) and Mck1, a member of
the glycogen synthase kinase 3 (GSK-3) protein family. When the serines were mutated to
alanines or in the absence of Mck1, Rcan1 was no longer able to stimulate calcineurin signalling
resulting in inhibition [35]. Phosphorylation by TAK1, DYRK1A and NIK all switch RCAN1
from an inhibitor to a calcineurin facilitator [33] [32] [34]. At odds with most studies, phos‐
phorylation of the serine residues within the SP motif of RCAN1 was reported to enhance its
ability to inhibit calcineurin [23].
In summary, although the mechanisms responsible for the dual role of RCAN1 in the calci‐
neurin signalling pathway is still under investigation, the results so far indicate that the
primary function of RCAN1 is to facilitate calcineurin activity and this occurs when RCAN1
is expressed at lower or physiological levels. On the other hand, when RCAN1 is highly
expressed, it has a secondary role of inhibiting calcineurin signalling by interfering with the
interaction between calcineurin and NFAT.
5.2. GSK–3 signalling
Numerous studies outlined above have shown that GSK-3 phosphorylates RCAN1 to regulate
its function. Interestingly, GSK-3 activity can also be regulated by RCAN1. PC-12 cells over-
expressing RCAN1 displayed an increase in the absolute levels of GSK-3β protein, which in
turn increased its kinase activity towards Tau [67]. Tau protein is a known target of GSK-3
which in its hyperphosphorylated form has been implicated in the aetiology of Alzheimer’s
disease [67]. Exactly how RCAN1 regulates the abundance of GSK-3 remains undetermined,
but it seems that RCAN1 is acting at a post-transcriptional level as the amount of GSK-3β
mRNA did not change upon increasing RCAN1 expression [67].
5.3. The MAPK/ERK signalling pathway
The MAPK/ERK signalling pathway mediates signal transduction from cell surface receptors
to downstream transcription factors. This pathway plays a role in a number of cellular
processes including proliferation, growth, motility, survival and apoptosis [68]. As indicated
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above, MAPK was able to phosphorylate RCAN1 at S112 within the SP motif to prime its
subsequent phosphorylation by GSK-3. Moreover, the same study demonstrated that phos‐
phorylation of RCAN1 by MAPK allowed RCAN1 to become a substrate for calcineurin [31],
thus introducing a further level of control to keep the pathway operating at an optimal level.
5.4. The NFκβ inflammatory pathway
RCAN1 is also able to regulate the Nuclear factor κβ (NFκB) signalling pathway. NFκB is a
transcription factor that regulates target genes involved in many physiological processes,
including immunity, inflammation, cancer, synaptic plasticity and memory. Under normal
circumstances, NFκB exists as a dimer and is sequestered in the cytoplasm through its
interaction with an inhibitory molecule known as Inhibitor of κB (IκB). Upon stimulation of
the NFκB signalling pathway, IκB is degraded by the ubiquitin/proteasome pathway releasing
its inhibitory action on NFκB [69]. Degradation of IκB allows NFκB to translocate to the nucleus
where it acts to induce the expression of various target genes including the inflammatory genes
cyclooxygenase-2 (Cox-2) and interleukin 1 (IL-1) [69]. RCAN1 is able to negatively regulate
the NFκB signalling pathway by attenuating NFκB activation. When RCAN1 was over-
expressed in a glioblastoma cell line, it resulted in a decrease in the expression of a number of
NFκB target genes including COX-2, IL-8, monocyte chemoattractant protein 1 (MCP-1),
ICAM1 and VCAM1 [51]. This study demonstrated that RCAN1 inhibited NFκB signalling
through a mechanism that reduced the basal turnover rate of IκBα thereby enhancing its
stability [51]. By increasing the level of steady state IκBα, RCAN1 was able to exert anti-
inflammatory effects by preventing NFκB activation following stimulation with inflammatory
mediators such as TNFα and IL-1β.
Studies have also linked RCAN1 to NFκB signalling via other members of the pathway. For
example, RCAN1 is able to negatively regulate the mRNA expression of NFκB inducing
kinase (NIK) in PC-12 cells [70]. NIK is a member of the MAP kinase family which acts to
phosphorylate and activate IκB kinase α (IKKα). Once active, IKKα phosphorylates IκBα,
which in turn causes it to dissociate from NFκB, allowing the transcription factor to migrate
into the nucleus and activate target genes. If RCAN1 negatively regulates the expression of
NIK, IκB would remain bound to NFκB and inhibit NFκB signalling [33]. Interestingly, while
RCAN1 regulates  NIK  expression,  NIK also  acts  on RCAN1.  As mentioned above,  NIK
phosphorylates the C-terminal region of RCAN1, the end result of which is to reduce RCAN1
proteasomal-dependent degradation and increase the stability of RCAN1 protein [33]. The
functional consequences of this increased stability of RCAN1 on NFκB signalling have yet
to be determined; however consistent with the study described above [51] it seems likely
that elevated levels of RCAN1 would increase the stability of Iκβ which would in turn inhibit
the NFκB signalling pathway.
5.5. Angiogenesis
Angiogenesis is a physiological process involving the growth of new blood vessels essential
for embryonic development as well as growth and development throughout life. This process
has also been associated with disease states including inflammation, tumourigenesis and
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cardiovascular disease [71]. Angiogenesis is orchestrated by a balance between pro-angiogenic
factors and angiogenic inhibitors [72]. A critical mediator of angiogenesis is Vascular endo‐
thelial growth factor (VEGF) which acts to stimulate angiogenesis and vascular permeability
[73-75]. VEGF stimulation of cells causes the rapid activation and translocation of NFAT into
the nucleus which in turn results in the up regulation of numerous genes associated with
angiogenesis [76]. A number of studies have implicated RCAN1 in angiogenesis. Early studies
found that RCAN1 mRNA increased by 6-fold when endothelial cell lines were treated with
VEGF [77, 78] and RCAN1 protein increased in human aortic endothelial cells (HUVECs)
similarly treated [49, 79]. RCAN1 gene expression was also up regulated by other mediators
of angiogenesis including thrombin [80].
Both major RCAN1 isoforms are involved in angiogenesis and appear to be regulated by
different mechanisms. When human endothelial cells were treated with VEGF, there was an
induction of RCAN1-4 mRNA after 30 min, with the highest levels observed after 1 hour.
Expression returned to basal levels by 24 hours after treatment [79, 81]. Others reported that
up regulation of RCAN1-4 during angiogenesis was mediated by calcium and calcineurin
signalling, because treatment with cyclosporine A (CsA), a calcineurin inhibitor, or intracel‐
lular calcium chelators prevented its up regulation [80, 82]. Further evidence to suggest that
RCAN1-4  was regulated by calcineurin signalling came from studies demonstrating that
RCAN1-4  expression following VEGF and thrombin treatment  was  dependent  upon the
cooperative binding of transcription factors NFAT and GATA to the RCAN1-4 promoter [80].
RCAN1-1 expression also appears to be modulated during angiogenesis. While initial studies
found that RCAN1-1 was not induced following VEGF treatment [79, 81], more recent reports
have indicated that RCAN1-1 is up regulated in cultured endothelial cells treated with VEGF
and during angiogenesis in vivo [49, 83]. However, unlike expression of RCAN1-4 during
angiogenesis,  RCAN1-1  expression  does  not  appear  to  be  regulated  by  the  calcineurin
signalling  pathway  as  its  expression  was  unaffected  by  treatment  with  either  CsA  or
intracellular calcium chelators [80, 82].
A number of reports have suggested that RCAN1-1 and RCAN1-4 may play opposing roles
in angiogenesis, where RCAN1-1 appears to be pro-angiogenic and is capable of inducing the
formation of new blood vessels, while RCAN1-4 inhibits angiogenesis and vessel formation.
For example, siRNA-mediated silencing of RCAN1-1 in HUVECs inhibited VEGF-induced
endothelial cell proliferation and angiogenic responses [49]. Further, when RCAN1-1 was over-
expressed in these cells it induced angiogenesis even in the absence of VEGF. This effect was
also observed in vivo when human skin melanoma (SK-MEL-2) cells, which over-express
VEGF-A, were transfected with RCAN1-1, implanted into a matrigel and transplanted into
mice. In this situation, exogenous expression of RCAN1-1 in SK-MEL-2 cells induced angio‐
genesis and vessel formation [49]. In contrast, RCAN1-4 appears to be anti-angiogenic as over-
expression of RCAN1-4 in SK-MEL-2 cells inhibited angiogenesis and siRNA-mediated
silencing of RCAN1-4 enhanced VEGF-induced proliferation [49]. Another study [80] found
that forced up regulation of RCAN1-4 in primary endothelial cells resulted in a reduction in
the expression of many pro-angiogenic genes, including cell cycle inhibitors and growth
factors and cytokines involved in the formation of new blood vessels, and moreover, the
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formation of tube structures (as a model for blood vessel development) formed from primary
human endothelial cells in vitro was inhibited. Consistent with this, B16 melanoma cells
engineered to over-express RCAN1-4 and implanted subcutaneously into C57BL6 mice
displayed a reduction in tumour growth due to a decrease in blood vessel density [80].
Interestingly, RCAN1-4 is thought to exert its anti-angiogenic effects by providing a negative
feedback loop to inactivate calcineurin, preventing nuclear translocation and transcriptional
activity of NFAT after VEGF stimulation. In support of this, ablation of RCAN1-4 expression
in endothelial cells increased NFAT activity and was associated with increased transcription
of NFAT-regulated genes, such as E-selectin and VCAM1 [78]. Intriguingly, RCAN1-1 was
found to activate NFAT activity and enhance is pro-angiogenic functions [49]. Thus, RCAN1-4
inhibits the calcineurin/NFAT pathway while RCAN1-1 activates it.
6. The consequences of RCAN1 over-expression in the DS brain
6.1. Down syndrome and the neural system
DS is the leading genetic cause of intellectual impairment in the general population and is
thought to contribute to around 30% of all cases of moderate to severe mental retardation [84].
Mental retardation in DS is characterised by behavioural and cognitive impairments which
include low IQ, language deficits and defects in both short and long term memory. Later these
deficits are compounded by the early onset of dementia [85].
People with DS exhibit a reduced performance on a number of different tests designed to
demonstrate short term or working memory, including visual perception, visual imagery and
spatial imagery tasks [86]. Long term memory is also affected by DS with both implicit (defined
as improvement in perceptual, cognitive or motor tasks without any conscious reference to
previous experience) and explicit (intentional recall or recognition of experiences or informa‐
tion) memory impaired [87]. In addition to the cognitive defects observed throughout life,
neuropsychological tests showed that there is a cognitive decline in DS individuals with age
and these cognitive changes equate to those observed following the onset of dementia [88]. DS
participants with early stage dementia displayed severely diminished long term memory as
well as a decreased ability to retrieve stored information compared with the non-demented
DS controls [88]. The decline in these forms of cognition, particularly the ability to form new
long term memories, is analogues to the cognitive deterioration seen in early to moderate
Alzheimer’s disease (AD) [89]. Interestingly, the cognitive defects that characterise DS are
associated with hippocampal-based learning and memory while prefrontal-mediated execu‐
tive function and cognition remain relatively unaffected [85].
The cognitive impairments in DS are accompanied by many neuro-morphological changes.
Individuals with DS have a significant reduction in brain weight and volume [90], despite brain
weight falling within the normal range at birth [91]. DS brains have a shorter anterior-posterior
diameter, a reduction in the size of the frontal lobes, a flatter occipital lobe and a smaller brain
stem and cerebellum [91]. The anterior and posterior corpus callosum regions and hippocam‐
pus are also smaller [92-95]. The hippocampus is a key brain structure involved in learning
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and memory and many of the behavioural and cognitive defects seen in DS are hippocampal-
dependent [85]. The difference in hippocampal volume is most likely due to various structural
abnormalities, including a decrease in the mean area of the dentate gyrus (DG) and inadequate
migration of cells into the pyramidal cell layer [96]. Notably, in adults there is an additional
age-related decrease in the volume of the hippocampus, most likely due to some degree of
neurodegeneration [95].
Smaller brains in DS individuals probably result from a reduction in the total number of
neurones, with certain regions preferentially affected. DS brains exhibit a decrease in neuronal
density by adulthood of between 10-50% [91]. The cortex of DS adults exhibits decreases in
neuronal number and density in addition to abnormal distribution of neurones [97]. This same
pattern of neuronal loss was also observed in the hippocampus and visual cortex. Interestingly,
DS foetuses exhibited the same pattern of neuronal development as normal foetuses, with
similar neuronal morphology, dendritic spine number and density [98]. However shortly after
birth defects were evident and became more pronounced with age [99]. This indicates that
something happens after birth which results in alterations in neuronal number and morphol‐
ogy. Using Golgi staining which allows for the visualisation of neurones including their cell
bodies, axons, dendrites and spines, the brains of DS infants exhibited shorter basilar dendrites
with a significant decrease in the absolute number of spines [100], which was postulated to
correlate with a 20-35% decrease in surface area per synaptic contact [91]. Why and how this
decline in neuronal development occurs is currently undetermined. These same defects were
observed in adults with DS, who exhibited decreased dendritic branching, dendrite length and
spine density [101]. Biochemical examination of adult DS brains also revealed a significant
reduction in the concentrations of various neurotransmitter markers including, noradrenaline,
serotonin or 5-hydroxytraptamine (5-HT) and choline acetyltransferase (ChAT) [102, 103],
again signifying neuro-functional deficits in the brain.
On top of the neurodevelopmental problems associated with DS, all individuals with the
disorder develop the neuropathological and neurochemical changes associated with AD by
the third decade of life [89]. This includes the accumulation of amyloid β (Aβ), formation of
hyperphosphorylated Tau-containing neurofibrillary tangles (NFT) and senile plaques. The
progression of AD-neuropathology is analogous in both DS and AD, despite occurring decades
earlier in DS [104].
6.2. RCAN1 in the brain
RCAN1 has been implicated in development and function of the brain. Rcan1 is expressed in the
developing mouse neural tube from embryonic day (E) E9.5 onwards and at E11.5-E12.5 was
detected in the telencephalic vesicles, the caudal hypothalamus, the pretectum and the basal
plate of the hindbrain and spinal cord. In later stages of embryonic development, Rcan1 was
highly expressed in the neural proliferative and differentiation zones within the brain with lower
expression observed in other regions, including the telecephalon, hypothalamus, pretectum,
cortical plate, striatum, amygdala, midbrain, hindbrain and spinal cord. In the post natal brain
Rcan1 gene expression was widely distributed throughout, with the highest levels in the olfactory
bulb, the cerebral cortex, hippocampus and dentate gyrus, striatum and septum, amygdala,
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hypothalamus and the habenula. Within the hippocampus and dentate gyrus, highest levels of
expression were observed in the pyramidal and granular cell layers [105].
Western blot analysis using an antibody designed to detect both RCAN1-1 and RCAN1-4
proteins found that the two isoforms were differentially expressed in the adult mouse brain.
RCAN1-1 was abundant throughout the brain, with the highest levels of expression detected
in the cortex and hippocampus [20, 54, 106]. RCAN1-4 was generally found at lower levels in
the hippocampus, striatum, cortex and prefrontal cortex [54]. Similar results have been
observed in the adult human brain where RCAN1-1 was most highly expressed in the cerebral
cortex, hippocampus, substantia nigra, thalamus and medulla oblongata [21]. It is worth noting
that while one study indicated that both isoforms of RCAN1 were located exclusively within
neurones and not in astrocytes or microglial cells [107], another study found a wider distri‐
bution pattern [106], with RCAN1-1 and RCAN1-4 detected in multiple cell types including
astrocytes and microglia. The highest levels of expression were observed in neurones [106].
Moreover, RCAN1-1 was also detected in primary glial-like cell cultures containing microglial
cells and expression of RCAN1-4 was strongly induced following calcium stress [106].
Experimental evidence suggests that RCAN1 has a role in brain function. For example, studies
on the RCAN1 orthologue in Drosophila known as nebula, demonstrated that a loss-of-function
mutation of nebula displayed a decrease in learning and memory acquisition and performed
significantly worse on learning and memory tests after a single trial compared with WT
controls. Testing after 1 hour found no difference in the short term memory performance,
however tests of long term memory (after 24 hours) found that nebula-deficient flies displayed
virtually no long term memory [108]. This defect was apparent despite the normal presence
of mushroom bodies (the learning and memory centres in Drosophila). The decrease in learning
and memory observed was attributed to abnormal calcineurin signalling, as nebula loss-of-
function mutants exhibited a 40% increase in calcineurin activity [108]. Interestingly, over-
expression of nebula resulted in a similar phenotype. When Drosophila over-expressing nebula
were generated and tested, they displayed virtually no ability to learn. This study also found
that transient over-expression of nebula was sufficient to cause learning and memory deficits,
indicating that a biochemical defect was responsible for learning and memory rather than a
pre-existing developmental abnormality [108], a finding that may have implications for DS
treatment options.
Similar behavioural abnormalities were observed in RCAN1-KO mice. While the absence of
Rcan1 did not result in any gross anatomical changes within the brain, RCAN1-KO mice
exhibited various behavioural and synaptic deficiencies. For example, RCAN1-KO mice were
shown to have impaired learning and memory in the Morris Water Maze (MWM), a well-
established paradigm of hippocampal-dependent learning and memory. During the acquisi‐
tion phase of the trial, RCAN1-KO mice displayed a decreased ability to learn the location of
the platform compared with WT controls. This indicated that RCAN1-KO mice had a spatial
learning impairment. These mice also displayed a poor spatial memory because when the
escape platform was removed, RCAN1-KO mice did not demonstrate a specific preference for
the target quadrant. On the other hand, a passive avoidance test using electric shock found
that long- and short-term contextual fear memory was normal in these mice [54]. Taken
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together results from this study suggested that the absence of Rcan1 selectively affects some,
but not all, types of memory.
These behavioural deficits in RCAN1-KO mice were accompanied by abnormal synaptic
transmissions and impaired long term potentiation (LTP). LTP is a form of synaptic plasticity
hypothesised to be a biological substrate for some forms of memory [109]. Two forms of LTP
can be examined: early-component LTP (E-LTP), a weak and short-lived enhancement of
synaptic transmission; and late-component LTP (L-LTP) which is a robust enhancement of
synaptic transmission lasting many hours [110, 111]. Paired-pulse facilitation (PPF) is also a
component of LTP and is a measure of pre-synaptic short-term plasticity and neurotransmitter
release [112]. Absence of RCAN1 did not affect the basal level of synaptic transmission but did
result in a reduction in PPF compared with the WT controls, suggesting that pre-synaptic short
term plasticity was affected by the lack of Rcan1. While there was no difference in the E-LTP,
L-LTP was adversely affected by the ablation of Rcan1, with RCAN1-KO mice exhibiting a
reduction in initial amplitude of L-LTP as well as a reduction in duration of the potentiation
[54]. This is significant because the amplitude and duration are the biological correlates of
synaptic strength required to reinforce the laying down of memory.
The strongest evidence to suggest a role for RCAN1 in the neurological defects observed in
DS comes from a recent study by our group examining RCAN1 transgenic (RCAN1-TG) mice.
Using mice engineered to over-express RCAN1-1 at a level analogous to that observed in DS,
we found up regulation of RCAN1 contributed to some of the neurological defects character‐
istic of DS. For example, RCAN1 over-expression resulted in multiple defects in the formation,
structure and function of the hippocampus [55]. Specifically, there was a significant reduction
in the overall size of the hippocampus and analysis of the various structures within the
hippocampal formation revealed a decrease in the absolute volume and cellularity of the
dentate gyrus [55], mirroring the structural hippocampal defects and marked neuronal loss
observed in DS. Our study suggested that the decrease in neuronal cellularity within the
hippocampus of RCAN1-TG mice was the result of defective neurogenesis because fewer
terminally differentiated neurones within the dentate gyrus formed and progenitor cells
isolated and cultured from the sub ventricular zone had diminished ability to differentiate into
neurones. This also reflects changes observed in DS [113]. RCAN1 transgenic mice also
exhibited neuro-physiological impairments. In particular, over-expression of RCAN1 resulted
in a defect in the maintenance phase of LTP which may be explained in part, by the reduction
in post-synaptic spine density observed in the brains of these mice. Failure to maintain LTP in
hippocampal slices was accompanied by deficits in hippocampal-dependent spatial learning
and in short and long term memory. At a molecular level, in response to LTP induction, we
observed diminished calcium transients and decreased phosphorylation of CaMKII and
ERK1/2, signifying that the processes essential for the maintenance of LTP and formation of
memory [55] are defective in mice with an excess of RCAN1.
RCAN1 has also been shown by our group to be involved in neurotransmission. Using
chromaffin cells cultured from the adrenal gland as a model for the neuronal system, cells from
both RCAN1-TG and RCAN1-KO mice displayed a reduction in neurotransmitter release. Our
study demonstrated that the normal function of RCAN1 was to regulate the number of synaptic
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vesicles fusing with the plasma membrane and undergoing exocytosis, and the speed at which
the vesicle pore opens and closes [53]. Although our study showed that the final outcome was
the same whether RCAN1 was in excess or deficit, increased expression of RCAN1 had the
opposite effect to Rcan1 ablation on vesicle fusion kinetics - ablation slowed fusion pore kinetics
while over-expression accelerated fusion pore kinetics.
6.3. RCAN1 in neurodegeneration
Although it has not been proven, there is circumstantial evidence to suggest that RCAN1 plays
a role in neurodegenerative conditions (other than DS). For example, Northern blot analysis
of human brain samples found that RCAN1 expression was increased about 2-fold in brains
of AD patients [21, 107]. This increased gene expression was confined to the regions of the
brain affected by AD, such as the hippocampus and cerebral cortex. This study also found that
regions of the brain containing NFT had up to 3 times more RCAN1 mRNA compared with
the same regions of the brain without tangles [21]. Immunohistochemistry on human brain
tissue using a RCAN1-specific antibody, found that RCAN1 protein levels increased in
abundance with normal ageing in pyramidal neurones with further increases observed in
brains affected by moderate to severe AD [65, 107]. In addition to increased protein levels,
there was an alteration in the subcellular location of RCAN1 in AD-affected neurones, with a
significant increase in the amount of RCAN1 within the nucleus compared with non-diseased
tissue [65]. Interestingly, there was an up regulation of RCAN1-1 mRNA and protein in the
hippocampus of AD patients, with no changes observed in the abundance of RCAN1-4 [65,
107], suggesting divergent functions of the major isoforms.
While these observations are intriguing, the question remains, what effect does increased
RCAN1 expression have on the ageing brain and does it play a role in AD-like neuropathology?
While this question remains unanswered, there are a number of possible reasons as to why
increased RCAN1 expression might lead to neurodegeneration. One proposed explanation
invokes a possible relationship between elevated RCAN1 expression, AD-like neurodegener‐
ation and Tau protein. Tau is involved in the stabilisation of the microtubule networks within
neurones and its hyperphosphorylation has been linked to the pathogenesis of AD. Tau can
be phosphorylated by a number of different kinases, including GSK-3β and Ca2+/calmodulin-
dependent protein kinases (CaMK). Hyperphosphorylation of Tau is detrimental and can lead
to AD neuropathology, including formation of NFT [114-116]. During normal cellular proc‐
esses, there is a proteasome-dependent degradation of Tau protein but when Tau becomes
hyperphosphorylated, it is resistant to this degradation and accumulates within the cell [117].
Some studies have found that increased levels of RCAN1 result in a concomitant increase in
the phosphorylation of Tau and thus may contribute to its neuronal accumulation [67, 117]
and we showed an accumulation of hyperphosphorylated Tau in the brains of aged RCAN1-
TG mice [118]. This observed enhancement in Tau phosphorylation may be due to the effect
of RCAN1 on GSK-3 activity, since increased RCAN1 expression in PC-12 cells resulted in an
increase in the absolute level of GSK-3β, which in turn enhanced its ability to phosphorylate
Tau [67]. There have also been suggestions that excess RCAN1 can exacerbate AD-like
neuropathology by inhibiting calcineurin. Calcineurin activity is decreased in AD [119] and
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hyperphosphorylated tau protein and cytoskeletal changes in the brain similar to those
observed in AD accumulate when the phosphatase activity of calcineurin is reduced [120].
Thus, if RCAN1 is behaving as a calcineurin inhibitor it is possible that increased levels of
RCAN1, as occurs in DS and AD, promote the development of AD [21] [121].
RCAN1, via its role as an inhibitor of calcineurin, has also been implicated in the pathogenesis
of Huntington’s disease (HD). In a mouse model of HD, phosphorylation of huntingtin at
serine residue 421 was protective and treatment of HD neuronal cells with calcineurin
inhibitors prevented their death by maintaining their phosphorylation status at Ser421 [122].
RCAN1-1L protein was significantly down regulated in human HD post mortem brains and
exogenous expression of RCAN1-1L in a cell culture model of HD protected the cells against
toxicity caused by mutant huntingtin [123]. This protection was attributed to the ability of
excess RCAN1 to inhibit calcineurin phosphatase activity, indicating that in this circumstance
RCAN1 over-expression is advantageous.
Another connection between RCAN1 and neurodegeneration may be through the formation
of aggregates. When proteins accumulate within a cell a mitrotubule-based apparatus known
as an aggresome acts to sequester proteins within the cytoplasm. The formation of aggresomes
within cells is most likely a defence mechanism against the presence of misfolded or abnormal
proteins. However if these misfolded proteins are not cleared appropriately it can lead to
abnormal protein accumulation and eventual neurotoxicity [124]. The formation of aggre‐
somes is believed to contribute to many neurodegenerative disorders including AD, Hun‐
tington’s disease and cerebral ataxia [125]. When RCAN1 was over-expressed in various
neuronal cell lines and in primary neurones, formation of aggregates occurred [124] and the
aggregates were associated with microtubules, indicating that they had formed inclusion
bodies within the cells. When RCAN1 was aggregated within neurones, neuronal abnormal‐
ities characterised by a decreased number and density of synapses were observed, which in
turn altered synaptic function [124]. This constitutes another example of the damaging effects
of excess RCAN1.
Finally, two polymorphisms located in the RCAN1-4 promoter region have been associated
with AD in the Chinese Han population [126]. One of these, rs71324311, in the heterozygous-
deletion genotype confers protection while the other, rs10550296, also in the heterozygous-
deletion configuration, is a risk factor. The functional consequences of these sequence variants
are yet to be determined.
7. The consequences of RCAN1 over-expression in the DS immune system
7.1. The Down syndrome immune system
DS is associated with a multitude of immune system defects. People with DS are more
susceptible to infections, particularly respiratory tract infections with pneumonia one of the
major causes of early death [127]. The incidence of viral hepatitis and haematopoietic malig‐
nancies is also increased in people with DS as is their tendency to develop certain types of
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autoimmune disorders such as autoimmune thyroid disease (AITD) (Hashimoto type), coeliac
disease and diabetes [127] [128]. Thus, DS appears to include a combination of immunodefi‐
ciency and immune dysfunction. Although the precise cause of this immune dysfunction is
unclear, the DS immune system is characterised by a number of abnormalities thought to
originate from defective innate and adaptive immunity.
7.2. Impairments in innate immunity
Innate immunity is the body’s first line of defence against invasion. This arm of the immune
system either prevents the entry of pathogens into the body, or upon entry, eliminates them
before they can cause any damage or disease. If a pathogen is able to gain entry into the body,
innate immunity includes various non-specific mechanisms which can eliminate and destroy
foreign invaders. These mechanisms include phagocytosis and inflammation. DS is associated
with defects in the innate immune system. For example, natural killer (NK) cells, components
of the innate immune system involved in the recognition and elimination of bacteria, viruses
and tumour cells, are defective in DS individuals [129]. Also, neutrophils from DS people
exhibited a decreased ability to phagocytose [130] and the ability of DS-derived neutrophils
and monocytes to migrate towards a site of injury or infection in response to chemokine release
was reduced [131].
7.3. Impairments in adaptive immunity
T cell development and maturation occurs within the thymus. Bone marrow (BM) derived
precursor cells migrate into the thymus where they receive developmental cues from the
thymic microenvironment. Here they progress through a number of different stages of
development broadly defined by the expression of CD4 and CD8 on the cell surface. Once cells
become fully mature, expressing only CD4 or CD8 on the surface, they are able to migrate to
the periphery and populate the immune system. The DS immune system is characterised by
a number of abnormalities thought to originate from defective T cell development in the
thymus. Typically, the DS thymus is small and morphologically abnormal. It exhibits cortical
atrophy, loss of cortico-medullary demarcation and lymphopenia due to a defect in the
development of thymocytes [114]. The number of cells expressing high levels of the TCR α-β-
CD3 complex is reduced [132] as are the numbers of helper (CD4+) T (Th) cells resulting in the
inversion of the normal CD4+/CD8+ ratio in favour of the CD8+ population. Th cells can be
further subcategorised into either Th1 or Th2 cells where Th1 cells participate in the elimination
of intra-vesicular pathogens, including bacteria and parasites via the activation of macro‐
phages, while Th2 cells clear extracellular pathogens and toxins by assisting antibody pro‐
duction in B cells. There is an imbalance in the T helper responses of DS individuals, although
there is some disagreement as to whether it is an alteration in the Th1 or Th2 phenotype. Some
studies have suggested that Th2 responses are augmented in DS based on the observation that
there is an increased number of circulating CD3+/CD30 Th2 lymphocytes [133]. Others report
an increase in the Th1 population in DS and this has been attributed to increased IFNγ
production [134] because IFNγ polarises Th0 cells towards the Th1 phenotype. While there is
no doubt that a defect in T cell development and maturation within the DS thymus exists,
Down Syndrome188
altered apoptosis of lymphocytes may also contribute to the decrease in overall numbers of T
cells in the periphery, as well as to the alterations observed in the abundance of the various T
cell subsets. For example, DS CD3+ T cells and CD19+ B cells expressed significantly higher
levels of early apoptotic markers compared with control cells [135].
T lymphocytes isolated from DS people are also functionally compromised. Under conditions
designed to simulate an infection using anti-CD3 antibodies or the non-specific mitogen,
phytohemagglutinin to activate T cells, DS lymphocytes were diminished in their proliferative
capacity [136, 137]. Not only did the DS-derived T cells have a proliferative defect, they showed
increased expression of apoptotic markers including APO-I/Fas (CD95) antigen, a T cell death
marker, and increased apoptosis was demonstrated in cultured T cells using Annexin V [138].
CD8+ or cytotoxic T lymphocytes (CTLs) isolated from DS individuals were also compromised
in their ability to kill target cells [139], indicating a functional defect in this cell type also. DS-
derived T cells also produce abnormal levels of cytokines, the small proteins produced by
immune cells that are involved in signalling and controlling immune responses. IL-2 is central
to the proliferation and differentiation of T cells and is produced by T lymphocytes once
activated. Inhibition or reduction in IL-2 results in suppression of the immune system. One
study on adults with DS found that the levels of IL-2 secreted from cultured stimulated T cells
were significantly reduced compared with T cells cultured from normal individuals [140].
Other studies have suggested that IL-2 is produced at comparable levels in both DS and normal
individuals, but in DS the response to IL-2 may be defective [141]. Levels of IFN-γ and TNF
α are also altered in DS and although the number of DS studies is small, the consensus is that
IFN- γ and TNF α levels are increased [142] [134].
In addition to T cell lymphopenia, DS individuals have marked B lymphopenia [143-145]. As
well as a reduction in the number and proportions of B lymphocytes, there is a skewing of the
B cell subpopulations, suggesting that maturation of B cells is defective in DS [146] akin to the
situation with T cells, although the exact nature of this defect has not been explored. Immu‐
noglobulin levels in DS are also abnormal, with DS B lymphocytes producing lower levels of
IgM, IgG2 and IgG4 and higher levels of IgG1 [146, 147]. IgG3 and IgA levels were unchanged.
Also suggesting a B cell functional deficit is the finding that antibody responses to a variety of
antigens are low in DS, including the responses to pneumococcal and bacteriophage ØX174
antigens and to vaccine antigens such as tetanus, influenza A and polio [148-150].
7.4. RCAN1 in innate immunity
There is evidence to indicate that RCAN1 has a role in innate immunity and inflammation. For
example, when human mononuclear cells were activated with Candida albicans, a pathogen
capable of eliciting an innate immune response, RCAN1 gene expression was rapidly induced
[151]. RCAN1 expression was also induced in response to various pro-inflammatory cytokines
involved in the innate immune system such as TNFα [78]. Other studies have found that
RCAN1 regulates inflammatory mediators and cytokines that have previously been identified
as components of the innate immune system. For example, forced over-expression of RCAN1
in endothelial cells using adenoviral vectors resulted in a decrease in the expression of
inflammatory markers such as E-selectin, VCAM1, TNF and COX-2 mRNA [78]. This sug‐
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gested that increased expression of RCAN1 may dampen inflammation and inhibit induction
of the innate immune system. Conversely, knockdown of RCAN1 using siRNA resulted in an
increase in the expression of inflammatory mediators [78].
Importantly,  RCAN1  also  mediates  inflammatory  responses  in  vivo.  When  mice  were
administered with lipopolysaccharide (LPS), a component of gram negative bacteria cell wall
used experimentally to activate innate immune responses, Rcan1 gene expression was induced
[152]. Interestingly, RCAN1-KO mice had lower survival following LPS-induced endotoxae‐
mia  compared  with  their  WT  littermates  [152].  Knockout  mice  had  an  accentuated  re‐
sponse to LPS treatment, including lower heart rate, blood pressure and body temperature.
An increase in the concentration of circulating IL-6 protein, a pro-inflammatory cytokine
believed to be detrimental during infection was also found, along with a significant increase
in the mRNA expression of inflammatory mediators such as E-selectin, ICAM1 and VCAM1
in organs including the heart and lung. There was a concomitant increase in the number of
infiltrating  leukocytes  within  these  organs  [152].  On the  other  hand,  over-expression  of
RCAN1-4 achieved by the intravenous injection of mice with a RCAN1-4-containing adeno‐
virus, conferred a survival advantage upon LPS administration. A decrease in the levels of
circulating IL-6 and an attenuation of the physiological  responses to systemic LPS treat‐
ment were evident [152]. Induction of inflammatory mediators was also reduced and there
was a marked reduction in leukocyte infiltrate in the heart, liver and lungs [152]. Another
study found that following infection with the bacteria Fransicella tularensis, induction of pro-
inflammatory cytokines including MCP1, IL6, IFNγ, and TNFα was significantly higher in
Rcan1-deficient spleen and lung [153]. All this suggests that over-expression of RCAN1 is
protective.
Other studies on the role of RCAN1 in innate immunity have focussed on identifying the
mechanisms by which RCAN1 regulates inflammation. One plausible means is by modula‐
tion of the NFκB signal transduction pathway. As described earlier, RCAN1 is able to inhibit
NFκB  signalling  by  increasing  the  stability  of  IκB  protein  [51].  Given  that  NFκB  is  a
transcription factor that controls the expression of pro-inflammatory genes and the subse‐
quent activation of innate immune cells,  negative regulation of this pathway by RCAN1
would result in inhibition of inflammation. Such a proposition is consistent with published
in vitro and in vivo data. However, another study investigating the potential involvement of
RCAN1 in the Toll-like receptor (TLR) pathway arrived at the opposite conclusion [154]. The
TLR pathway is activated as a first line defence mechanism during microbial infection and
culminates in the induction of  interleukins and other pro-inflammatory mediators  [155].
When RCAN1-4 (DSCR1-1S) was exogenously expressed in HEK293 cells, the end result was
activation of NFκB-mediated inflammatory responses [154], not suppression. Here, RCAN1
was found to regulate the TLR pathway through a direct interaction with the adaptor protein
known as Toll-interacting protein (Tollip). The normal cellular role of Tollip is to suppress
TLR signalling by sequestering IL-1  receptor  associated kinase  1  (IRAK-1).  Exogenously
added  RCAN1  bound  Tollip,  causing  the  release  of  IRAK-1  from  the  complex  thereby
removing the block on IRAK-1 activity [154]. The end result was an enhancement of the
inflammatory response and thus represents yet another example of the sometimes contradic‐
tory actions of RCAN1.
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7.5. RCAN1 in adaptive immunity
The first evidence to suggest that RCAN1 functions in adaptive immunity came from experi‐
ments investigating T cell responses in human Jurkat cells, an immortalised T lymphocyte cell
line. When these cells were stimulated with the T cell mitogens, CD3 and CD28, expression of
RCAN1-4 mRNA was induced [26]. This result was confirmed by stimulating primary T cells
cultured from humans [156]. A more definitive role for RCAN1 in the adaptive immune system
came from examining RCAN1-KO mice [44]. While these mice displayed normal T cell develop‐
ment and maturation with comparable numbers of mature thymocytes and equivalent num‐
bers of CD4+, CD8+, CD3+ T cells in the periphery, these cells exhibited functional deficits. When
the T cells were isolated from the spleen and cultured ex vivo, the RCAN1-KO cells were
functionally defective. Specifically, these T cells exhibited a 50% reduction in proliferation in
response to mitogenic stimulation as well as a decrease in the production of IFNγ. This loss of
IFNγ indicated that the Th1 population was especially affected by the lack of Rcan1 expres‐
sion. Indeed, these mice exhibited defective Th1 responses due to the premature death of this
population of cells as a result of an up regulation of FasL and a loss of viability. Antibody class
switching was also altered in RCAN1-KO mice, with a decrease in IgG2 production. Notably,
the T cell defect in RCAN1-KO mice could be rescued by treatment with the calcineurin inhibitor,
CsA, suggesting that the defect was calcineurin/NFAT-dependent and presumably due to
hyperactivation of the calcineurin signal transduction pathway [44]. However, despite restora‐
tion of T cell function in RCAN1-KO mice following CsA treatment, genetic loss of calcineurin
Aβ superimposed on the Rcan1 deficiency by crossing RCAN1-KO mice with CnAβ knockout
mice, could not rescue the T cell defects [64]. In fact, loss of calcineurin Aβ in addition to the loss
of Rcan1 resulted in an increase in the severity of the T cell defect. This observation suggests that
in these mice RCAN1 is acting to facilitate calcineurin activity rather than inhibit it as the use of
CsA treatment had suggested. Our group also has evidence of RCAN1’s involvement in adaptive
immunity; our RCAN1-TG mice have T and B cell defects (unpublished data and manuscript in
preparation).
In addition to its function in T cells, RCAN1 is involved in the normal function of mast cells. Mast
cells are specialised immune cells that contain granules rich in histamine and heparin and are
known to play a role in wound healing, defence against pathogens and the pathology of IgE-
dependent allergic disease and anaphylaxis [157]. Mast cells are activated through the high
affinity IgE receptor (FcεRI) on their cell surface and this activation is controlled by a number of
activating and inhibitory molecules. The down regulation of mast cell activity by inhibitory
signals is essential in preventing allergic disease and anaphylaxis [157]. RCAN1 is believed to
be one of these inhibitory signals. Evidence to suggest this comes from experiments conduct‐
ed on RCAN1-KO mice, which displayed an exaggerated mast cell response. While RCAN1-
KO mice displayed normal mast cell maturation, many of the signalling pathways following
mast cell activation were perturbed. For example, mast cells isolated from RCAN1-KO mice and
stimulated with FcεRI had an increase in the activation of both the NFAT and NFκB signalling
pathways. As expected, there was also an increase in the expression of many pro-inflammato‐
ry genes regulated by these two pathways including IL-6, IL-13 and TNFα [158]. Further, when
mice lacking Rcan1 were sensitised with an intravenous injection of anti-IgE antibody and then
later treated with an agent designed to elicit an anaphylactic reaction, Rcan1 deficiency led to
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enhanced mast cell activation, degranulation and passive cutaneous anaphylaxis [158]. These
results indicate that RCAN1 may be an inhibitor molecule that negatively controls mast cell
function.
Eosinophils, another immune cell type, are predominant effector cells in allergic asthma and
their presence in the lungs of asthma sufferers is regarded as a defining feature of this
inflammatory disease. Absence of Rcan1 was shown to prevent experimentally-induced
allergic asthma in a mouse model due to an almost complete absence of eosinophils infiltrating
the lungs [159]. Although the exact mechanism for this protection is not fully understood, it
seems that a lack of Rcan1 blocks the development and migration of eosinophil progenitors
from the bone marrow and selectively lowers their production of the inflammatory mediator
IL-4. This study implies that over-expression of RCAN1 would exacerbate the allergic response
and in this regard it is interesting to note that a recent study reported an increased incidence
of allergic asthma in people with DS [160]. Therefore, it would be very informative to test
allergic asthma responses in RCAN1-TG mice.
8. The consequences of RCAN1 over–expression on the incidence of solid
tumours in DS
8.1. Down syndrome and cancer
Individuals with DS are more likely to develop certain malignancies, especially of the immune
system. There is a well-established link between leukaemia and DS, with an increased inci‐
dence in DS compared with the general population. Large population based studies conduct‐
ed in different countries around the world have consistently found that the rates of leukaemia
were between 10- to 19-fold higher in people with DS in comparison with the average popula‐
tion and there was an increased incidence of both lymphoid and myeloid leukaemias [140,
161-163]. While the incidence of both acute myeloid leukaemia (AML) and acute lymphatic
leukaemia (ALL) was significantly higher in DS subjects than expected in the general popula‐
tion, there were significantly more cases of AML compared to ALL in DS [163]. This increased
risk is most evident at a younger age, however remained throughout life. There is also a significant
increase in the incidence of neoplastic disorders such as megakaryoblastic leukaemia, where the
incidence is increased about 500-fold in DS [164, 165]. In males, there is also a link between DS
and testicular cancer, possibly due to higher levels of follicular stimulating hormone, hypogo‐
nadism or cryptorchidism [166, 167]. Notably, those with DS are less likely to develop other solid
tumours such as neuroblastomas and breast and lung cancers [162, 163, 168]. Indeed, DS
individuals had a 50% reduction in the incidence of solid tumours compared to the number of
cases expected in the general population and this was observed over all age groups examined
[162]. Thus it seems likely that a number of tumour suppressor genes reside on Hsa21.
8.2. RCAN1 and tumourigenesis
While the identities of the Hsa21 genes responsible for the reduction in solid tumour formation
in DS remain unknown, there is evidence to suggest that up regulation of RCAN1 may afford
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some protection. Firstly, a number of cancers display abnormal expression of RCAN1 and this
expression varies depending on the stage of the cancer. For example, studies have shown that
RCAN1 is up regulated in most primary papillary thyroid tumours but this expression is lost
in the metastatic tissue of thyroid tumours [169]. This is interesting given that RCAN1 has been
identified as a target gene for metastatin, a protein that functions to suppress metastatic tumour
growth. It is possible that loss of metastatin in tumour cells leads to a loss of RCAN1 expression
which may in turn contribute to tumour metastasis [169]. RCAN1 has also been linked to other
cancers including colorectal cancer. Peroxisome proliferator-activated receptor γ (PPARγ) is
a member the nuclear hormone receptor family of transcription factors and has been identified
as a tumour suppressor gene in colon cancer. This gene is important in a number of cellular
processes including inflammation, proliferation, apoptosis as well as adipocyte and intestinal
epithelial cell differentiation and has been shown to suppress experimental colon carcinogen‐
esis in mice (reviewed in [170]). Loss of RCAN1-4 in MOSER colon carcinoma cells resulted in
an inhibition of PPARγ-mediated tumour suppression and increased tissue invasion [171].
While not conclusive, these results indicate that RCAN1 may be required for PPARγ suppres‐
sion of colorectal cancers [171]. Again this is consistent with the idea that RCAN1 can act as a
tumour suppressor.
The strongest genetic evidence to suggest a role for RCAN1 in tumourigenesis comes from
experiments conducted on RCAN1-KO and RCAN1-TG mice. When RCAN1-KO mice were
injected subcutaneously with renal carcinoma or colon carcinoma tumour cells, there was a
significant suppression of tumour growth [172]. Tumour growth was suppressed due to an
inability  to  form  and  maintain  tumour  vasculature  within  the  solid  tumours.  Further
investigation  showed  that  RCAN1-KO  mice  had  hyperactive  VEGF-calcineurin-NFAT
signalling, which resulted in a suppression of endothelial cell proliferation and an increase
in apoptosis  [172].  Tumour growth in the RCAN1-KO mice could be restored following
treatment with CsA, suggesting that suppression of tumour cell growth in RCAN1-KO mice
was dependent on hyperactive calcineurin signalling. Perhaps counterintuitively, but similar
to the situation with the RCAN1-KO, mice over-expressing RCAN1-4 were also resistant to
tumour growth when injected subcutaneously with Lewis lung or B16F10 tumour cells [173].
Tumours isolated from these mice also displayed a decrease in the density of microvessels
and the vessels lacked a functional lumen. Moreover, it appeared that RCAN1-4 mediated
tumour growth through the calcineurin pathway as RCAN1-4 transgenic tumour cells had a
decrease in both calcineurin and NFAT activity [173]. The exact mechanisms by which RCAN1
suppresses solid tumour growth remain unknown, but both studies strongly suggest that
regulation of angiogenesis by RCAN1 underpins the inhibition of tumour growth by reducing
the formation of blood vessels throughout the tumour. It is interesting to note that RCAN1-
KO and RCAN1-TG mice displayed a similar phenotype, with both exhibiting a decrease in
tumour formation due to an inhibition of angiogenesis preventing the formation of microves‐
sels required to support tumour growth. Perhaps more intriguing is that opposite effects on
the calcineurin pathway produced the same end result. Also intriguing is that microvessel
formation was also decreased in teratomas generated from human DS-derived pluripotent
stem  cells  transplanted  into  WT  mice,  indicating  that  decreased  angiogenesis  may  be
responsible for tumour suppression in DS [173].
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Finally, the significance of RCAN1 in tumour suppression in DS was elegantly demonstrated
using yet another DS genetic model. TS65Dn mice that harbour a third copy of many Hsa21-
orthologous genes, including Rcan1, were bred with RCAN1-KO mice, thereby returning the
gene dosage of Rcan1 to normal. When tumour cells were injected into these mice, there was
a significant increase in the formation of microvessels within solid tumours compared with
their TS65Dn littermates expressing 3 copies of Rcan1 [173]. This is more evidence to support
the idea that elevated levels of RCAN1 are responsible, at least in part, for the decrease in the
incidence of solid tumour formation in DS.
Figure 2. Summary of the positive and negative effects of excess RCAN1. Effects on the brain, immune system
and solid tumour formation in Down syndrome are shown. The putative contributions of an over abundance of
RCAN1 have either been demonstrated in mouse models or in cell lines or implied from Rcan1-KO studies where, in
the absence of data to the contrary, the assumption is that over-expression will produce the opposite effect to the
deficiency. Detrimental effects are shown in blue and protective effects in yellow.
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9. Conclusion
In this review we have attempted to summarise what is currently known about the function
of the RCAN1 gene and its pleiotropic actions in three areas of relevance to DS (see Figure 2).
No matter which system you look at, the reports on RCAN1 function are often contradictory
– we still have much to learn. Researchers with a passionate interest in DS and its molecular
genetic aetiology have suggested that specific down regulation of a few of the genes produced
in excess in DS tissues may provide an avenue for therapies. We and others have suggested
that inhibition of RCAN1 signalling may have pharmacological potential for reducing
neuronal loss and treating cognitive decline in DS and AD, but we still have much to learn
about the molecular function and physiological role of RCAN1 and how we can manipulate
its activity to ameliorate/treat pathology.
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